Terms: = Brain cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
42 results:
1. Ribosomal S6 protein kinase 4 promotes resistance to ezh2 inhibitors in glioblastoma.
Pang F; Zhang L; Li M; Yi X; Wang Y; Yang P; Wen B; Jiang J; Teng Y; Yang X; Chen L; Xu J; Wang L
Cancer Gene Ther; 2023 Dec; 30(12):1636-1648. PubMed ID: 37726387
[TBL] [Abstract] [Full Text] [Related]
2. Targeting ezh2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
Zhao G; Deng Z; Li X; Wang H; Chen G; Feng M; Zhou Y
Exp Brain Res; 2023 Oct; 241(10):2409-2418. PubMed ID: 37644332
[TBL] [Abstract] [Full Text] [Related]
3. Identification of genomic biomarkers and their pathway crosstalks for deciphering mechanistic links in glioblastoma.
Quddusi DM; Bajcinca N
IET Syst Biol; 2023 Aug; 17(4):143-161. PubMed ID: 37277696
[TBL] [Abstract] [Full Text] [Related]
4. Molecular and clinical diversity in primary central nervous system lymphoma.
Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
[TBL] [Abstract] [Full Text] [Related]
5. A novel model based on necroptosis-related genes for predicting immune status and prognosis in glioma.
Yuan YS; Jin X; Chen L; Liao JM; Zhang Y; Yu KW; Li WK; Cao SW; Huang XZ; Kang CM
Front Immunol; 2022; 13():1027794. PubMed ID: 36389690
[TBL] [Abstract] [Full Text] [Related]
6. Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by ezh2 overexpression.
Chen X; Chen Y; Chen X; Wei P; Lin Y; Wu Z; Lin Z; Kang D; Ding C
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166534. PubMed ID: 36057370
[TBL] [Abstract] [Full Text] [Related]
7. ezh2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects.
Paskeh MDA; Mehrabi A; Gholami MH; Zabolian A; Ranjbar E; Saleki H; Ranjbar A; Hashemi M; Ertas YN; Hushmandi K; Mirzaei S; Ashrafizadeh M; Zarrabi A; Samarghandian S
Biomed Pharmacother; 2022 Feb; 146():112532. PubMed ID: 34906772
[TBL] [Abstract] [Full Text] [Related]
8. Combination LSD1 and HOTAIR-ezh2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
Zhao J; Jin W; Yi K; Wang Q; Zhou J; Tan Y; Xu C; Xiao M; Hong B; Xu F; Zhang K; Kang C
Pharmacol Res; 2021 Sep; 171():105764. PubMed ID: 34246782
[TBL] [Abstract] [Full Text] [Related]
9. ezh2-mediated long-chain non-coding RNA LINC00963 promotes proliferation and invasion of glioma cells through inhibiting p21 expression.
Gai Q; Guo W; Liu J
J BUON; 2021; 26(2):380-387. PubMed ID: 34076983
[TBL] [Abstract] [Full Text] [Related]
10. ezh2 is a potential prognostic predictor of glioma.
Chen YN; Hou SQ; Jiang R; Sun JL; Cheng CD; Qian ZR
J Cell Mol Med; 2021 Jan; 25(2):925-936. PubMed ID: 33277782
[TBL] [Abstract] [Full Text] [Related]
11. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation.
Senthil Kumar S; Sengupta S; Zhu X; Mishra DK; Phoenix T; Dyer L; Fuller C; Stevenson CB; DeWire M; Fouladi M; Drissi R
Mol Cancer Res; 2020 Nov; 18(11):1711-1723. PubMed ID: 32801164
[TBL] [Abstract] [Full Text] [Related]
12. Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (ezh2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma.
Sasaki T; Katagi H; Goldman S; Becher OJ; Hashizume R
Neurosurgery; 2020 Nov; 87(6):E680-E688. PubMed ID: 32674144
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic role of H3K27M mutation, histone H3K27 methylation status, and ezh2 expression in diffuse spinal cord gliomas.
Ishi Y; Takamiya S; Seki T; Yamazaki K; Hida K; Hatanaka KC; Ishida Y; Oda Y; Tanaka S; Yamaguchi S
Brain Tumor Pathol; 2020 Jul; 37(3):81-88. PubMed ID: 32529280
[TBL] [Abstract] [Full Text] [Related]
14. Expression and prognostic role of E2F transcription factors in high-grade glioma.
Yu H; Li Z; Wang M
CNS Neurosci Ther; 2020 Jul; 26(7):741-753. PubMed ID: 32064771
[TBL] [Abstract] [Full Text] [Related]
15. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.
Enomoto T; Aoki M; Hamasaki M; Abe H; Nonaka M; Inoue T; Nabeshima K
Neurol Med Chir (Tokyo); 2020 Mar; 60(3):136-146. PubMed ID: 31902873
[TBL] [Abstract] [Full Text] [Related]
16. Long non-coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL.
Yan J; Xu C; Li Y; Tang B; Xie S; Hong T; Zeng E
J Cell Mol Med; 2019 Aug; 23(8):5518-5531. PubMed ID: 31240814
[TBL] [Abstract] [Full Text] [Related]
17. Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through ezh2 and LSD1.
Luo W; Li X; Song Z; Zhu X; Zhao S
Aging (Albany NY); 2019 Jun; 11(11):3811-3823. PubMed ID: 31186379
[TBL] [Abstract] [Full Text] [Related]
18. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (ezh2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract] [Full Text] [Related]
19. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel ezh2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
[TBL] [Abstract] [Full Text] [Related]
20. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract] [Full Text] [Related]
[Next]
